Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Saved in:
| Title: | Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). |
|---|---|
| Authors: | Stein Gold LF; Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA., Bagel J; Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USA., Tyring SK; Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine, The University of Texas Medical School at Houston, Houston, TX, USA., Hong HC; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.; Probity Medical Research, Surrey, BC, Canada., Pavlovsky L; Tel Aviv University, Tel Aviv, Israel.; Rabin Medical Centre, Petah Tikva, Israel., Vender R; Dermatrials Research, Hamilton, ON, Canada.; Venderm Consulting, Hamilton, ON, Canada., Pinter A; Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Reich A; Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland., Drogaris L; AbbVie Inc., North Chicago, IL, USA., Wu T; AbbVie Inc., North Chicago, IL, USA., Patel M; AbbVie Inc., North Chicago, IL, USA., Soliman AM; AbbVie Inc., North Chicago, IL, USA., Photowala H; AbbVie Inc., North Chicago, IL, USA., Stakias V; AbbVie Inc., North Chicago, IL, USA., Richter S; AbbVie Inc., North Chicago, IL, USA., Papp KA; Probity Medical Research and Alliance Clinical Trials, Waterloo, ON, USA.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada. |
| Source: | The British journal of dermatology [Br J Dermatol] 2023 Oct 25; Vol. 189 (5), pp. 540-552. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37488811 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Stein+Gold+LF%22">Stein Gold LF</searchLink>; Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.<br /><searchLink fieldCode="AU" term="%22Bagel+J%22">Bagel J</searchLink>; Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Tyring+SK%22">Tyring SK</searchLink>; Department of Dermatology, Microbiology and Molecular Genetics and Internal Medicine, The University of Texas Medical School at Houston, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+HC%22">Hong HC</searchLink>; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.; Probity Medical Research, Surrey, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Pavlovsky+L%22">Pavlovsky L</searchLink>; Tel Aviv University, Tel Aviv, Israel.; Rabin Medical Centre, Petah Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Vender+R%22">Vender R</searchLink>; Dermatrials Research, Hamilton, ON, Canada.; Venderm Consulting, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Pinter+A%22">Pinter A</searchLink>; Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.<br /><searchLink fieldCode="AU" term="%22Reich+A%22">Reich A</searchLink>; Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland.<br /><searchLink fieldCode="AU" term="%22Drogaris+L%22">Drogaris L</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Wu+T%22">Wu T</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Patel+M%22">Patel M</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Soliman+AM%22">Soliman AM</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Photowala+H%22">Photowala H</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Stakias+V%22">Stakias V</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Richter+S%22">Richter S</searchLink>; AbbVie Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Papp+KA%22">Papp KA</searchLink>; Probity Medical Research and Alliance Clinical Trials, Waterloo, ON, USA.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220004041%22">The British journal of dermatology</searchLink> [Br J Dermatol] 2023 Oct 25; Vol. 189 (5), pp. 540-552. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0004041 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2133 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070963%22">00070963 </searchLink><i>NLM ISO Abbreviation: </i>Br J Dermatol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37488811 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/bjd/ljad252 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 540 Titles: – TitleFull: Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Stein Gold LF – PersonEntity: Name: NameFull: Bagel J – PersonEntity: Name: NameFull: Tyring SK – PersonEntity: Name: NameFull: Hong HC – PersonEntity: Name: NameFull: Pavlovsky L – PersonEntity: Name: NameFull: Vender R – PersonEntity: Name: NameFull: Pinter A – PersonEntity: Name: NameFull: Reich A – PersonEntity: Name: NameFull: Drogaris L – PersonEntity: Name: NameFull: Wu T – PersonEntity: Name: NameFull: Patel M – PersonEntity: Name: NameFull: Soliman AM – PersonEntity: Name: NameFull: Photowala H – PersonEntity: Name: NameFull: Stakias V – PersonEntity: Name: NameFull: Richter S – PersonEntity: Name: NameFull: Papp KA IsPartOfRelationships: – BibEntity: Dates: – D: 25 M: 10 Text: 2023 Oct 25 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1365-2133 Numbering: – Type: volume Value: 189 – Type: issue Value: 5 Titles: – TitleFull: The British journal of dermatology Type: main |
| ResultId | 1 |
